World News – AU – ObsEva Appoints David Renas as Chief Financial Officer


. .

Geneva, Switzerland and Boston, MA – 4. January 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical biopharmaceutical company that develops and commercializes novel therapies to improve the reproductive health of women, today announced the appointment of David Renas as Chief Financial Officer (CFO) and Member of the company’s Executive Committee effective today. He will be stationed in the U.. S.. .

« David has a proven track record of leadership and we are excited to welcome him to the executive team, » said Brian O’Callaghan, ObsEva’s chief executive officer. “I am confident that he will play a key role in further strengthening our relationships with investors and potential partners as we prepare to file a new drug application (NDA) in the US. S.. . in the first half of 2021 for Yselty to treat heavy menstrual bleeding and fibroid pain in pre-menopausal women and to advance ebopiprant to treat premature labor following the recent publication of our positive Ph II data. « I would also like to thank our Chief Administrative Officer (CAO), Fabien de Ladonchamps, for the wonderful job he has done as interim CFO. « .

David Renas joins ObsEva with more than 30 years of experience in finance and law, including 15 years in the pharmaceutical and life science industries. Most recently he was CFO at Petra Pharma and CFO and General Counsel at Sangart, where he led the company through 11 clinical studies in 20 countries. David Renas was also a partner at Adkins Black LLP. Prior to focusing on the life science industry, he was a private practice attorney with Gray Cary Ware & Freidenrich (now DLA Piper) and Foley & Lardner, and CPA with Deloitte. David Renas holds a Bachelor of Arts degree in economics from Stanford University and a doctorate in law from the University of California at Davis.

“I am delighted to be able to participate in the development of ObsEva at such an important time as CFO, which recently submitted an MAA to the European Medicines Agency (EMA) for its flagship product Yselty for uterine fibroids an expected NDA filing in 1H 2021. I look forward to working with the extraordinary team on this exciting journey, ”said David Renas.

ObsEva is a biopharmaceutical company that develops and commercializes novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline of development programs focused on the treatment of endometriosis, uterine fibroids, premature birth, and improving embryo transfer outcomes after in vitro fertilization. ObsEva is listed on the Nasdaq Global Select Market and is traded under the ticker symbol « OBSV » and on the SIX Swiss Exchange under the ticker symbol « OBSN ». . For further information go to www. ObsEva. com.

All statements contained in this press release that are not historical facts may be forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements can be identified by words such as « believe, » « expect, » « may, » « plan, » « potentially, » « will » and similar expressions and are based on ObsEva’s current beliefs and expectations. These forward-looking statements include expectations regarding the clinical development of ObsEva’s product candidates and ObsEva’s plan to file its MAA in Europe and the NDA in the United States. These statements involve risks and uncertainties that could cause actual results to differ materially from those contained in these statements. Risks and uncertainties that could cause actual results to differ materially include uncertainties associated with the conduct of clinical trials, clinical development, and related regulatory interactions. ObsEva’s reliance on third parties that the Company may not always have full control over, as well as the impact of the Coronavirus Outbreak novel and other risks and uncertainties detailed in the Risk Factors section of ObsEva’s Annual Report on Form 20-F for December 31, 2017. The fiscal year ending December 2019. The risk factors are set out in ObsEva’s Report on Form 6-K filed with the Securities and filed with the Exchange Commission (SEC) on Dec.. November 2020 and other filings ObsEva files with the SEC. These documents are available on the investor page of the ObsEva website at www. ObsEva. com. All forward-looking statements speak only as of the date of this press release and are based on information available to ObsEva as of the date of this press release. ObsEva assumes no obligation and does not intend to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Press release in pdf

Obseva Logo4 (00000002). jpg

ObsEva, CFO, Finance, Nasdaq

World News – AU – ObsEva appoints David Renas as CFO
Related Title :
ObsEva Appoints David Renas as Chief Financial Officer
ObsEva appoints David Renas CFO – Quick Facts



Abonnez-vous à notre chaîne Youtube en cliquant ici: EBENE MEDIA TV

Vidéo du jour:

Donnez votre point de vue et aboonez-vous!


Votre point de vue compte, donnez votre avis

[maxbutton id= »1″]